ClinConnect ClinConnect Logo
Search / Trial NCT00503815

BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

Launched by BRAINTREE LABORATORIES · Jul 18, 2007

Trial Information

Current as of July 21, 2025

Completed

Keywords

Colonoscopy Bowel Preparation Prep

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • -Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
  • Evaluation of BE results GI bleeding Anemia of unknown etiology Neoplastic disease surveillance Endosonography Inflammatory bowel disease Unknown diarrhea or constipation etiology Polypectomy Laser therapy Routine Screening
  • At least 18 years of age
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
  • Exclusion Criteria:
  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal and decompression.
  • Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
  • Subjects with a history of renal or hepatic insufficiency or congestive heart failure.
  • Subjects who had previous gastrointestinal surgeries
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.

About Braintree Laboratories

Braintree Laboratories is a leading clinical trial sponsor dedicated to advancing medical research and innovation in the pharmaceutical and biotechnology sectors. With a strong commitment to developing high-quality, safe, and effective therapies, Braintree Laboratories collaborates with healthcare professionals and research institutions to design and conduct rigorous clinical trials. The organization specializes in a wide range of therapeutic areas and employs state-of-the-art methodologies to ensure the integrity and reliability of trial results. Braintree Laboratories is focused on improving patient outcomes and contributing to the global healthcare landscape through its dedication to scientific excellence and ethical research practices.

Locations

Nashville, Tennessee, United States

Germantown, Tennessee, United States

Bellevue, Washington, United States

Houston, Texas, United States

Anaheim, California, United States

Orange, California, United States

Jackson, Mississippi, United States

Franklin, Ohio, United States

Portland, Oregon, United States

Patients applied

0 patients applied

Trial Officials

John D McGowan, B.S.

Study Director

Braintree Laboratories, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials